Press Releases

Five-year survival data from pivotal Phase 3 Study 309/KEYNOTE-775 trial evaluating lenvatinib plus pembrolizumab in certain patients with advanced endometrial carcinoma Efficacy outcomes in...

Multiple endometrial carcinoma abstracts to be presented, including long-term follow-up data for lenvatinib plus pembrolizumab in advanced disease from Study 309/KEYNOTE-775 Final bone metastases...

Long-Term Follow-Up Data from LEAP-002 Offers Insights into Hepatocellular Carcinoma Treatment Pipeline Data in Endometrial Carcinoma Among Studies to be Presented NUTLEY, N.J., May 20, 2025...

In the Phase 3 LEAP-012 trial, KEYTRUDA plus LENVIMA in combination with TACE reduced the risk of disease progression or death by 34% compared to TACE alone Late-breaking first interim analysis...

Late-breaking results from the Phase 3 LEAP-012 trial offer further insight into the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC); data are selected for...

Eisai today announced a label update for LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, in the United States to include clinical efficacy data for...

Eisai today announced results from a post-hoc analysis from the Phase 3 REFLECT trial, which looked at efficacy outcomes characterized by depth of response in patients with unresectable...

Biomarker Analyses from Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation Additional Data From Eisai's Pipeline Provide Insights...

Data from the Pivotal Phase 3 CLEAR Trial and Phase 2 KEYNOTE-B61 Trial Provide Further Insight into the Role of Lenvatinib Plus Pembrolizumab as a First-Line Treatment Option for Patients with...

Longer-Term Efficacy and Safety Results from the Phase 3 LEAP-002 Trial Offer Additional Information About the First-Line Treatment of Patients with Unresectable Hepatocellular Carcinoma Data on...

Data from the Pivotal Phase 3 CLEAR and Study 309/KEYNOTE-775 Trials Provide Valuable Information About the Treatment of Patients with Advanced Renal Cell Carcinoma and Certain Types of Advanced...

Final Pre-Specified Overall Survival Analysis from the Pivotal Phase 3 CLEAR Trial in Patients with Advanced Renal Cell Carcinoma Will Be Featured in an Oral Presentation NUTLEY, N.J., May 23,...

Initiative Features Compelling Stories Celebrating That People are "Made of More" Than Their Head and Neck Cancer Diagnosis, Along With Resources to Help People Impacted Find Support and Community...

Study Findings in Patients with Recurrent or Advanced Endometrial Carcinoma Who Were Rechallenged With Platinum Chemotherapy Will Be Featured in an Oral Plenary Session Additional Subgroup...

Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal Cancer Research from the...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN®, "eribulin") will be presented during the 2022 San Antonio...

Data Include Provider-Reported Best Overall Response (BOR), Progression-Free Survival and Overall Survival in U.S. Patients NUTLEY, N.J., Oct. 21, 2022 /PRNewswire/ -- Eisai today announced final...

RAHWAY, N.J. and NUTLEY, N.J., Sept. 10, 2022 – Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Eisai today announced the first presentation of results from the...

Analysis Evaluates Efficacy of Eribulin in Metastatic HER2-low Breast Cancer Across Three Studies (Presentation: #259P) NUTLEY, N.J., Sept. 10, 2022 /PRNewswire/ -- Eisai announced today results...

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular...

Campaign Provides Educational Resources on Liver Cancer and Encourages People to Make Some Daily Adjustments to Help Support Liver Health NUTLEY, N.J., Aug. 4, 2022 /PRNewswire/ -- Baseball legend...

RAHWAY, N.J. and NUTLEY, N.J., August 3, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Phase 3 LEAP-002 trial investigating...

Poster Discussion Features Investigational Safety and Efficacy Data from the Platinum-Resistant Ovarian Cancer Cohort Expansion of a Phase 1 Study Evaluating Farletuzumab Ecteribulin (MORAb-202)...

Data on Farletuzumab Ecteribulin (MORAb-202) Showcase Eisai's Advanced Chemistry Capabilities and Commitment to Identifying Novel Approaches in Treating Cancer to Improve Outcomes for Patients...

Spot Her Aims to Educate People About the Signs and Risk Factors of Endometrial Cancer, One of the Most Common Yet Under-Recognized Women's Cancers Actor Leads Spot Her Virtual Walk to Increase...

KENILWORTH, N.J., and NUTLEY, N.J., January 20, 2022 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the publication of results from the Phase 3...

Eisai announced today the presentation of six abstracts across various gastrointestinal cancers during the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium...

Eisai Inc. and METAvivor today announced the launch of fearLESS, a new initiative of the #ThisIsMBC campaign. FearLESS showcases content of a diverse group of 10 participants, who have a...

Eisai Inc. announced today the presentation of 13 abstracts across multiple types of cancer from its oncology portfolio during the upcoming European Society for Medical Oncology (ESMO) Congress...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Aug. 11, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 22, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...

TOKYO AND NEW YORK, June 18, 2021 -- Eisai Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the companies have entered into an exclusive global strategic collaboration...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., June 7, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced new investigational data from the...

Eisai today announced results from a real-world study assessing treatment patterns and clinical outcomes with HALAVEN® (eribulin mesylate) injection as a third-line therapy or greater in patients...

Eisai Inc. announced today the presentation of more than 25 abstracts across various types of cancer from its oncology portfolio during the virtual scientific program of the 2021 American Society...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 6, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai Inc. today announced that the U.S. Food and Drug...

Eisai announced today that the European Journal of Cancer published the results from a post hoc analysis of the Phase 3 SELECT study evaluating the impact of lung metastases on overall survival...

Eisai Inc. announced today the launch of Spot Her—an initiative to end the silence around endometrial cancer, a type of uterine cancer, and inspire women to listen, advocate and put their health...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., March 19, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of...

Eisai will present two abstracts at the virtual Society of Gynecologic Oncology (SGO) 2021 Annual Meeting on Women's Cancer, March 19-25 (#SGOMtg). These investigational data include the first...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Feb. 13, 2021 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced the first presentation of new...

Eisai will present four abstracts at the virtual Genitourinary Cancers Symposium 2021 (#GU21) from February 11-13, 2021. These investigational data include a late-breaking oral presentation from...

Eisai will present five abstracts across four tumor types at the Gastrointestinal Cancers Symposium (#GI21), which is being held virtually from January 15-17, 2021. Investigational data on the...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Dec. 16, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the pivotal Phase 3...

Eisai Inc. and METAvivor today announced the launch of Perseverance, a new initiative of the #ThisIsMBC campaign. Perseverance showcases imagery of a diverse group of 12 participants capturing the...

Eisai announced results from Study 211 evaluating the safety and efficacy of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, at two starting doses:...

Eisai announced today the presentation of three abstracts including investigational data in thyroid cancer and osteosarcoma at the European Society for Medical Oncology (ESMO) Asia Virtual...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., November 10, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data...

Eisai announced results from Study 218, a Phase 2 trial comparing the safety and efficacy of two different starting doses (18 mg versus 14 mg once daily) of LENVIMA, an orally available multiple...

Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 20, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new investigational data from two...

Eisai will present two late breakers and 10 e-posters at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21, 2020. Notable data from ongoing LEAP clinical...

Eisai Inc. announced today the topline results from Study 211, a Phase 2 trial evaluating the efficacy and safety of LENVIMA, an orally available multiple receptor tyrosine kinase inhibitor...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., July 8, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...

Eisai today announced updated results from ENHANCE 1, a Phase 1b/2 study exploring the investigational combination of eribulin plus pembrolizumab in patients with metastatic triple-negative breast...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., May 28, 2020 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced new data from analyses of two trials...

Eisai announced today the presentation of data and analyses across six cancer types at the American Society of Clinical Oncology's ASCO20 Virtual Scientific Program from May 29-31. Data from...

Eisai announced today that positive results from a Phase 2 study (Study 111/KEYNOTE-146) of lenvatinib (marketed as LENVIMA®), an orally available kinase inhibitor discovered by Eisai, in...

Eisai presented today results from a Phase 2 trial assessing the efficacy and safety of lenvatinib (marketed as LENVIMA®) in combination with everolimus (LEN+EVE) in patients with unresectable...

Eisai announced today the presentation of three abstracts at the 2020 Genitourinary Cancers Symposium (#GU20) in San Francisco from February 13-15. New data to be presented on lenvatinib (marketed...

Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and #Cancerland to fearlessly unite the breast cancer community and shine a spotlight...

Eisai announced today the presentation of three abstracts at the 2020 Gastrointestinal Cancers Symposium (#GI20) in San Francisco from January 23-25. New data to be presented on lenvatinib...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 42nd San Antonio...

Eisai Inc. and METAvivor today announced the launch of Beneath the Breast, a new initiative of the #ThisIsMBC campaign. Beneath the Breast spotlights imagery of eight people living with metastatic...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 29, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full...

Eisai today announced the presentation of new data and analyses via one oral proffered paper presentation, four poster discussions and seven poster presentations at the 2019 European Society for...

KENILWORTH, N.J., and WOODCLIFF LAKE, N.J., Sept. 17, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...

Kenilworth, N.J., and Woodcliff Lake, N.J., July 23, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug...

Eisai today announced additional data from an ongoing Phase 1 trial exploring the investigational combination of eribulin and balixafortide, a CXCR4 antagonist, in patients with HER2-negative...

Eisai today announced the presentation of new data and analyses in one oral presentation, 11 posters at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4 in...

Eisai announces today that one mini-symposium and 15 poster presentations from its oncology pipeline will be highlighted at the American Association for Cancer Research (AACR) 110th Annual Meeting...

Eisai announced today that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN®) following cyclin-dependent kinase (CDK) 4/6 inhibitor in...

Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and Project #Cancerland to bring to life the #ThisIsMBC Elements campaign through...

Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations...

Eisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign. Elements spotlights nine people living with metastatic breast cancer (MBC) and their...

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (marketed as HALAVEN®) will be presented during the 41st San Antonio...

Tokyo and Kenilworth, N.J., Nov. 9, 2018 – Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...

Eisai Inc. announced today the presentation of four abstracts at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Washington, D.C. from November 9-11. The data to be...

Eisai Inc. announced today the presentation of six abstracts featuring data and analyses on its cancer treatments at the European Society of Medical Oncology (ESMO) 2018 Congress taking place in...

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) approved the kinase inhibitor LENVIMA®...

TOKYO & KENILWORTH, N.J., July 31, 2018 – Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration...

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally...

Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has extended the action date for the...

Eisai Inc. today announced the presentation of new data and analyses at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting from June 1-5 in Chicago. The data to be presented...

Eisai Inc. announced today that the positive results of a Phase 3 study (REFLECT study, Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate (marketed as...

Eisai Inc. today announced the publication of results from a subgroup analysis of the pivotal Phase 3 study comparing eribulin mesylate (marketed as Halaven® Injection) with dacarbazine in...

Eisai Inc. announced today results from the independent imaging review (IIR) of the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple...

Eisai Co., Ltd. and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that they received Breakthrough Therapy Designation from the U.S. Food and Drug...

Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc.,...

Eisai Inc. today announced the U.S. Food and Drug Administration (FDA) accepted for review a supplemental New Drug Application (sNDA) for lenvatinib (marketed as Lenvima®) for the potential use...

Eisai Inc. today announced interim results from the advanced renal cell carcinoma (RCC) cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima® in the U.S. and...

Eisai Inc. announced today a delay in the deterioration of five health-related quality of life domains that affect patients' daily lives was observed in patients treated with lenvatinib as...

Eisai Inc. will present data from its lenvatinib (marketed as Lenvima®) clinical trial program in four difficult-to-treat cancers at the European Society of Medical Oncology (ESMO) 2017 Congress...

Eisai Inc. announced data from a prespecified subgroup analysis, which was published in the Journal of Clinical Oncology, showing treatment with lenvatinib (marketed as Lenvima®) resulted in a...

Eisai Inc. today announced it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for the first-line use of lenvatinib (marketed as Lenvima®), the...

Eisai Inc. today announced results from the REFLECT study (Study 304), a Phase 3 trial evaluating lenvatinib (marketed as Lenvima®), the company's multiple receptor tyrosine kinase inhibitor...

Eisai Inc. today announced interim results from the first evaluable cohort of Study 111, a Phase 1b/2 study investigating lenvatinib (marketed as Lenvima®), a multiple receptor tyrosine kinase...

Eisai Inc. announced today the presentation of new data and analyses at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3 – 7 in Chicago. The data to be presented...

Eisai Inc. announced today 13 presentations of clinical and preclinical research at the American Association for Cancer Research (AACR) 2017 Annual Meeting, April 1 – 5, 2017 in Washington, D.C....

Eisai Inc. today announced positive topline results from the randomized, multicenter Phase 3 trial (Study 304) evaluating the company's multiple receptor tyrosine kinase inhibitor, lenvatinib...